A new treatment option has become available for severe epilepsy: fenfluramine, which is now available on the NHS for children and adults living with Lennox–Gastaut syndrome (LGS).
Asymptomatic older patients of COVID-19 are one of the most difficult to identify - now, researchers find that delirium could be an indicator of the virus
Leading pancreatic cancer experts Professor Matthias Löhr and Professor Monique van Leerdam of United European Gastroenterology’s (UEG) Public Affairs Committee discuss the importance of early diagnosis and the latest developments in treatment for pancreatic cancer.
Eight days after the Pfizer vaccine results (90% effective) brought collective hope to the world, the Moderna vaccine has proven to be 95% effective at fighting COVID-19.
Over 350 million people suffer from arthritis pain globally, which means significant levels of opiates are used to manage the condition - but what if there was a less addictive treatment?
Muy-Teck Teh, Senior Lecturer from Barts and the London School of Medicine & Dentistry, Queen Mary University of London discusses how a novel low-cost rapid digital diagnostic test could help save lives and reduce head and neck cancer burden worldwide.
Cecilia Van Cauwenberghe from Frost & Sullivan’s TechVision Group, China charts how to deal with dementia during the COVID-19 pandemic, starting with a helpful global and regional overview.
Elena Posth & Romina Männl from Pfalzklinikum walk us through exactly how the company has entered into a new and exciting era of treating people with mental illness by charting their ‘Innovative psychiatry for the 21st century – Close to domicile. Competent. Human’ project.
US health insurance coverage decreased significantly, resulting in 25,180 excess deaths before COVID - researchers say this number will triple if the Affordable Care Act is overturned.
A new study, led by researchers at Queen Mary University of London, uses novel biomarkers to predict patient responsiveness to rheumatoid arthritis treatment.
Professor Martin Michaelis and Dr Mark Wass of University of Kent’s School of Biosciences, explain why a herd immunity approach to COVID-19 would include great risk, potentially many deaths, and may simply not work.
